Abstract
INTRODUCTION
Posaconazole, a novel triazole antifungal agent, is widely used for the prophylaxis and treatment of in vasive Aspergillus and Candida infection. Because posaconazole is a welltolerated antifungal agent [1] , posaconazoleassociated severe hyperbilirubinemia is usually rare in clinical practice. We herein report a case of a 57yearold man with acute myeloid leukemia (AML) following chemotherapy who developed severe hyperbilirubinemia and jaundice after posaconazole administration. The causality between posaconazole and the adverse event, the mechanism of posaconazole induced liver injury, and exacerbating risk factors were provided.
CASE PRESENTATION

History of present illness
A 58yearold man was diagnosed with AML (M2) in January 2018. Afterwards, he developed pulmonary infection, and his hepatic and renal function remained normal following a standard voriconazole dose (200 mg, ivgtt, q12h). He received idarubicin (10 mg, iv, qd, days 13) and cytarabine (75 mg, iv, q12h, days 17)
Song ZW et al . Posaconazole-associated hyperbilirubinemia following chemotherapy for chemotherapy on January 29, and bone marrow aspiration showed morphological complete remission. At the end of chemotherapy, gingival necrosis developed in the patient on February 5 accompanied with grey tissues and clusters attached to mouth mucosa, and fungal infection following chemotherapy was considered. Fungal quest through microscopic examination showed a positive result with obvious hyphae on February 8, but the specy remained unavailable. Since aspergillosis was suspected, the patient was treated with amphotericin B for gargling, amphotericin B liposome (100 mg, ivgtt, qd) and voriconazole (200 mg, ivgtt, q12h). On February 13, pathologic examination showed mucor mycosis (Rhizopus microsporus), and moderate renal damage was observed with a creatinine clearance (Ccr) level of 42.7 mL/min (normal range, > 80 mL/min) while liver function remained normal.
History of past illness
He had a healthy past history with no hepatic dys function before except for consumption of alcoholic beverages.
TREATMENT
Due to the moderate renal damage and to its poor efficacy for mucormycosis, voriconazole was discon tinued. The medication process was illustrated in Figure  1 . On February 15, his recovery from renal damage was evidenced by a Ccr level of 79.2 mL/min, while liver function remained normal. Posaconazole (400 mg, po, q12h) was prescribed together with amphotericin B. On two days postposaconazole, TBIL and direct bilirubin (D-BIL) rose to 93.3 μmol/L and 92.7 μmol/L, respectively, with progressive yellowish conjunctivae and skin (jaundice). Since druginduced liver injury (DILI) could not be excluded, amphotericin B was suspected to be the cause. The dosage of amphotericin B liposome was reduced to 80 mg/d, and single hepatic protector was prescribed. Hyperbilirubinemia and jaundice became progressively worse, and posaconazole was discontinued as an unconfirmed causative drug on four days postposaconazole while keeping amphotericin B (80 mg). Laboratory data on February 21 revealed progressive hyperbilirubinemia with a T-BIL (D-BIL) level of 159.9 (158.3) μmol/L. T-BIL reached a peak value of 170 μmol/L on February 22; then hepatic protectors were combined to treat hepatic dysfunction. On February 23, TBIL (DBIL) began to decrease to 155.3 (121.5) μmol/L with an ALP level of 739 U/L, a GGT level of 638 U/L and an ALT level of 98U/L, while other laboratory data continued to decrease. On February 27, hyperbilirubinemia related symptoms improved. In consideration that posaconazole was the causative drug and amphotericin B liposome was effective, the dosage of amphotericin B liposome was escalated gradually, and the symptoms improved gradually, while TBIL remained decreasing consistently.
OUTCOME AND FOLLOW-UP
Later, jaundice disappeared and oral infection impro ved significantly. With a stable healthy condition and relatively normal T-BIL [34.4 μmol/L, Upper Limit Of Normal (ULN) of 34 μmol/L] on March 11, the patient was discharged from hospital.
DISCUSSION
DILI is a serious medicationinduced complication with a prevalence of up to 14 out of 100000 people, accoun ting for 33% of acute liver failure cases [2] . Actually, posaconazoleinduced severe hyperbilirubinemia is a rare type of DILI, which has not been reported in case reports. In order to diagnose DILI, medication history, withdrawal response, response to unintentional re administration and laboratory evidence of hepatocellular or cholestatic injury will need to be combined. Liver biopsy may help identify nondrugrelated (alternative) causes and define the pattern of DILI. The RUCAM (Roussel Uclaf Causality Assessment Method) scale has been established to assess the causality of DILI and suspected drug [3] , and it provides a quantitative grade of causality for each suspected drug in a case report and a final score greater than 8 indicates the causal relationship that is highly probable [4] . Generally speaking, the mechanism of DILI remains incompletely understood. DILI can be classified as hepatocellular, cholestatic, or mixed type. At present, the calculation of R ratio [R = (ALT ÷ ALT's ULN) / (ALP ÷ ALP's ULN)] has been adopted to determine the pattern of DILI: R ≥ 5 defines hepatocellular, R ≤ 2 defines cholestatic and 2 < R < 5 defines a mixed liver injury [4] . In this case report, the patient had normal ba seline liver function at initial hospitalization. His liver function remained normal prior to posaconazole ad ministration but hyperbilirubinemia occurred on two days postposaconazole. Afterwards, posaconazole was discontinued, and symptomatic treatment (liver protective drugs) was prescribed. At four days after posaconazole withdrawal, TBIL began to decrease and was normalized with jaundice improving. Analyzing the medication history, his liver function remained normal during previous combination of voriconazole and amphotericin B liposome, and hyperbilirubinemia occurred after voriconazole withdrawal, excluding voriconazole. Besides, TBIL kept rising during amphotericin B liposome dose reduction, and TBIL remained decreasing consistently within single the rapy of amphotericin B liposome and escalading dura tion, excluding amphotericin B. After comprehensive analysis on his past history, medication process, causality identification, clinical manifestation and laboratory evidence of liver function, we considered that posaconazole was likely the causative drug for hyper bilirubinemia in this case, and the causality was highly probable with an RUCAM score of 9. Also, the calculated R value of 0.335 indicated that posaconazoleassociated severe hyperbilirubinemia in the case was cholestatic, but the precise pattern of DILI requires liver biopsy.
Plasma protein binding ratio of posaconazole is up to 98% [5] , and it is mainly metabolized through intrahepatic glucuronidation with an elimination halflife varying from 25 to 35 h. The majority of posaconazole (66%) are excreted unchanged in feces with less than 1% excreted unchanged in urine [6] . As a welltolerated antifungal agent, posaconazoleassociated severe hyperbilirubinemia is usually rare in clinical practice with unknown mechanism. One study demonstrates that mitochondrial dysfunction might account for DILI due to posaconazole [7] . When intracellular posa conazole accumulates, it decreases mitochondrial membrane potential, impairs the electron transport chain, causes mitochondrial superoxide accumulation and mitochondrial DNA decreasing, and finally induces hepatic cell apoptosis.
Interestingly, posaconazoleinduced hyperbili rubinemia is not necessarily linked with an elevated plasma concentration of posaconazole [8, 9] . On the contrary, hyperbilirubinemia may contribute to lowering plasma concentration of posaconazole [6] . Increased bilirubin competitively binds albumin with posacona zole, and plasmabound posaconazole decreases. On the other hand, increased bilirubin expedites the elimination of posaconazole through upregulation of glucuronidation.
As a welltolerated azole antifungal agent, posa conazole is relatively safe, but its pharmacokinetics varies in different patients [10] . DILI caused by posa conazole may be aggravated by risk factors in particular groups. According to the FDA instruction, under rare situations, severe liver complication might be worsened in patients with serious primary diseases such as hematological malignancy. In this case, there were several risk factors that can contribute to worsening liver injury. First, the patient was diagnosed with se vere systemic diseaseAML (M2). Second, he received chemotherapy, which potentially impaired his liver and renal function. He was under myelosuppression and febrile neutropenia following chemotherapy. Ad ditionally, he developed severe pulmonary infection with respiratory failure type I before chemotherapy, which might cause inadequate oxygen supply and carbon dioxide retention for organs. Potential early liver dysfunction could not be excluded completely despite normal laboratory values. Finally, voriconazole and amphotericin B had been prescribed earlier with moderate renal damage occurring before posaconazole administration, which might contribute to liver injury.
In summary, the case report describes a 58year old male patient with AML (M2) and a healthy past history who developed mucormycosis following che motherapy. After administration of posaconazole oral suspension, he developed severe hyperbilirubinemia and jaundice (CTCAEGrade 3). After posaconazole withdrawal and symptomatic treatment with liver protective agents, TBIL was normalized, and symp toms of jaundice disappeared gradually. After literature review, we considered that posaconazole was the causative drug with an RUCAM score of 9, and the severe hyperbilirubinemia was cholestatic type in this case. Additionally, DILI due to posaconazole may be linked with an intracellular concentration of posaconazole and mitochondrial DNA damage but not necessarily with elevated plasma concentration. The case demonstrates that, besides drug factors, DILI caused by posaconazole is closely related with patients' age, past medical history, the history of adverse events, concomitant diseases, and medication combination. The condition is usually very rare, and we have found no detailed description of it in the medical literature. Therefore, to the best of our knowledge, this is the first thoroughly documented case report of posaconazoleassociated severe hyperbilirubine mia. The case report provides instructive points for other healthcare professionals. When patients with hematological malignancy develop severe infection following chemotherapy, combination of antiinfective drugs may contribute to a higher risk of severe DILI. Therefore, to avoid severe adverse events, liver and renal function should be monitored closely before and during the administration of posaconazole.
CONCLUSION
The case report suggests that, to avoid severe adverse events, liver and renal function should be monitored closely before and during the administration of posa conazole, especially for patients with hematological malignancy.
